The use of ultrasound-guided fine-needle aspiration (FNA) biopsy for nonpalpable breast lesions varies considerably. This retrospective study stresses the role of breast FNA in evaluating sonographically suspicious nonpalpable breast masses using a probabilistic reporting system. One hundred and eight consecutive ultrasound-guided FNA biopsies diagnosed as positive (32), suspicious (8), atypical (11), benign (55), and unsatisfactory (2) were analyzed and correlated with 61 subsequent surgical specimens. All positive cytologies showed carcinoma on histology; suspicious cases were followed by 5 carcinomas, 2 fibroadenomas, and 1 papillary lesion. Follow-up of atypical cases included 4 carcinomas, 3 fibroadenomas, and 2 papillary lesions, while all 10 biopsies following benign cytology showed fibrocystic changes. Two cases with suspicious sonographic findings but unsatisfactory cytology had lobular carcinoma. The remainder of the benign and atypical cases were followed clinically and radiographically for at least 10 months and had no evidence of carcinoma. Positive predictive values were positive, 100%; suspicious, 63%; atypical, 36%; benign, 0%. Most (40/43; 93%) carcinomas were invasive. In conclusion, ultrasound-guided FNA for nonpalpable breast lesions is highly accurate, and probabilistic reporting helps direct patient management.

Download full-text PDF

Source
http://dx.doi.org/10.1002/dc.20068DOI Listing

Publication Analysis

Top Keywords

nonpalpable breast
16
breast lesions
12
ultrasound-guided fine-needle
8
fine-needle aspiration
8
probabilistic reporting
8
ultrasound-guided fna
8
carcinomas fibroadenomas
8
fibroadenomas papillary
8
atypical cases
8
breast
5

Similar Publications

Background: Most breast cancers are detected at an early stage in which case conservative surgery is indicated. An accurate preoperative localization technique is essential for conservative surgery of non-palpable breast lesions. Currently, the gold standard technique is wire localization (WL).

View Article and Find Full Text PDF

Background: Intraoperative ultrasound-guided breast-conserving surgery guarantees real-time direct visualization of tumor and resection margins. We compared surgical, oncologic, and cosmetic outcomes between intraoperative ultrasound-guided breast-conserving surgery and traditional (palpation- or wire-guided) surgery across all breast cancer lesion types.

Methods: This prospective observational cohort study was conducted at the Veneto Institute of Oncology between January 2021 and October 2022.

View Article and Find Full Text PDF

Assessing fetal radiation dose from iodine-125 seeds in pregnant breast cancer patients: an updated model.

Phys Med Biol

January 2025

Department of Medical Physics, Jeroen Bosch Ziekenhuis, Henri Dunantstraat 1, 's-Hertogenbosch, 5223GZ, NETHERLANDS.

The treatment of breast cancer during pregnancy requires careful consideration of consequences for both maternal and fetal health. In non-pregnant patients, the use of radioactive iodine-125 (125I)-seeds is standard practice for localising non-palpable breast tumors before breast-conserving surgery. However, the use of 125I-seeds in pregnant patients has been avoided due to concerns about fetal radiation exposure.

View Article and Find Full Text PDF

Purpose: To investigate the impact of artificial intelligence (AI) reading digital mammograms in increasing the chance of detecting missed breast cancer, by studying the AI- flagged early morphology indictors, overlooked by the radiologist, and correlating them with the missed cancer pathology types.

Methods And Materials: Mammograms done in 2020-2023, presenting breast carcinomas (n = 1998), were analyzed in concordance with the prior one year's result (2019-2022) assumed negative or benign. Present mammograms reviewed for the descriptors: asymmetry, distortion, mass, and microcalcifications.

View Article and Find Full Text PDF

Aim: This study aimed to detail our experience of using SCOUT® radar reflector for lesion localisation in the breast and axilla.

Materials And Methods: This is a prospective cohort study describing our clinical experience with the first 500 patients who received SCOUT® to localise lesions in the breast and axilla (from 23 July 2020 to 4 April 2022). Study measures include patient demographics, lesion location, diagnostic pathways (screening or symptomatic), imaging, and surgical and pathology outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!